High or standard initial dose of budesonide to control mild-to-moderate asthma? Source: Eur Respir J 2001; 17: 856-862 Year: 2001
Use of step-down design to study dose comparability of budesonide (B) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 534s Year: 2003
Systemic availability (lung deposition) of drug from two different dry powder inhalers in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002
Numerical simulation of the effect of inhalation parameters and disease severity on the deposition of dry powder aerosol drugs in COPD patients Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020
Dose comparability of fluticasone (F) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma using dose step-down study design Source: Eur Respir J 2003; 22: Suppl. 45, 534s Year: 2003
In-vitro emitted dose characteristics of combination budesonide / formoterol tubuhaler using patient inhalation profiles Source: International Congress 2015 – Lung function: waiting to exhale... Year: 2015
The small airway inflammation of asthmatic patients who have used dry powder type inhaled steroid for moderate-long term evaluated by induced sputum and the efficacy of HFA-BDP (QVAR) inhalation Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005
A novel NEXT DPI® dry powder inhaler and its use in asthmatic and COPD population Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
The effect of Yu-Ping-Feng capsules and Fu-Fang-Dan-Shen tablets on stable COPD Source: Annual Congress 2013 –COPD biomarkers Year: 2013
Beclomethasone, formoterol and glycopyrronium: synergy of dual and triple combinations in an ex vivo model of COPD exacerbation Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies Year: 2021
Dose- and exposure response analysis of glycopyrrolate (GP) metered dose inhaler (MDI) to support optimal dosing in patients with COPD for combination product development Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Comparative in vitro performance of the new drug aclidinium in a novel multidose dry powder inhaler Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 43s Year: 2001
Does the inhalation device affect the bronchodilatory dose response curve of Salbutamol in asthma- and COPD patients? Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003
Assessment of lung deposition and pharmacokinetics in 12 lung transplanted patients after inhalation of a novel liposomal ciclosporin a (CsA) formulation by the eFlow electronic nebuliser Source: Eur Respir J 2007; 30: Suppl. 51, 29s Year: 2007
Extrafine beclomethasone dipropionate aerosol therapy shows promising improved effect in treatment of children with stable asthma Source: Eur Respir J 2004; 24: Suppl. 48, 378s Year: 2004
Medical personnel‘s ability to use pressurized metered dose inhaler (pMDI) in India Source: Annual Congress 2006 - The challenges of managing asthma in primary care Year: 2006